Could an allergy drug tame COPD Flare-Ups?

NCT ID NCT07059091

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests if omalizumab (Xolair), an allergy drug, can reduce serious flare-ups in people with COPD who also have allergies. About 334 participants will receive injections of the drug or a placebo for 12 months. The goal is to see if the drug lowers the number of COPD exacerbations that require steroids or hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omalizumab (Xolair)
What this could lead to: If it works, this could provide a new treatment option to reduce COPD exacerbations in people who also have allergies.
What could go wrong: This is a Phase 2 trial, so it is still early. The drug may not reduce flare-ups as hoped, and side effects from injections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease chronic obstructive pulmonary disease lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLERGIES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

Baylor College of Medicine
NOT_YET_RECRUITING

Houston, Texas, 77030, United States
Columbia University
NOT_YET_RECRUITING

New York, New York, 10032, United States
Cornell University
NOT_YET_RECRUITING

New York, New York, 10032, United States
Duke University Medical Center
NOT_YET_RECRUITING

Durham, North Carolina, 27705, United States
Henry Ford Health
NOT_YET_RECRUITING

Detroit, Michigan, 48202, United States
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21231, United States
Mount Sinai, Icahn School of Medicine
NOT_YET_RECRUITING

New York, New York, 10029, United States
National Jewish Health
NOT_YET_RECRUITING

Denver, Colorado, 80206, United States
Northwestern University
NOT_YET_RECRUITING

Chicago, Illinois, 60611, United States
Pacific Northwest Airways - VA Puget Sound Healthcare System, Seattle
NOT_YET_RECRUITING

Seattle, Washington, 98108, United States
Rush University Medical Center
NOT_YET_RECRUITING

Chicago, Illinois, 60612, United States
Temple University
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19140, United States
University of Alabama
NOT_YET_RECRUITING

Birmingham, Alabama, 35294, United States
University of Arizona- Tuscon
NOT_YET_RECRUITING

Tucson, Arizona, 85724, United States
University of Florida
NOT_YET_RECRUITING

Jacksonville, Florida, 32209, United States
University of Illinois at Chicago
NOT_YET_RECRUITING

Chicago, Illinois, 60608, United States
University of Iowa
NOT_YET_RECRUITING

Iowa City, Iowa, 52242, United States
University of Kansas Medical Center
NOT_YET_RECRUITING

Kansas City, Kansas, 66160, United States
University of Michigan
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
University of San Francisco
NOT_YET_RECRUITING

San Francisco, California, 94143, United States
University of Vermont
NOT_YET_RECRUITING

Colchester, Vermont, 05446, United States
Vanderbilt University Medical Center
NOT_YET_RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.